Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus paclitaxel and cisplatin as neoadjuvant therapy for esophageal cancer
ChiCTR1900021783Phase 4Recruiting
- Sponsor
- Anyang Cancer Hospital
- Start
- Jun 2019
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib, paclitaxel and cisplatin in esophageal cancer, sponsored by Anyang Cancer Hospital. Primary endpoint: objective response rate. Started Jun 2019; status: recruiting.
02
Drugs
Rivoceranibpaclitaxelcisplatin
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on ChiCTR1900021783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021783.